, Tracking Stock Market Picks
Enter Symbol:
Medgenics, Inc. (MDGN) [hlAlert]


Medgenics, Inc. (MDGN) rated Buy with price target $12 by Needham

Posted on: Thursday,  Nov 12, 2015  8:25 AM ET by Needham

Medgenics, Inc. (AMEX: MDGN)
rated Buy with price target $12 by Needham.

Medgenics, Inc., a commercial-stage biopharmaceutical company, focuses on providing protein therapies. The company develops the Biopump Platform, a proprietary technology, which uses the patient?s own tissue to continuously produce and deliver the patient?s own protein therapy. It is designed to provide protein therapy to treat a range of chronic diseases, including anemia, hepatitis C, hemophilia, multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases or conditions. The company?s product line includes EPODURE, a Biopump producing erythropoietin in Phase I/II clinical trial to treat anemia in patients with chronic kidney disease; INFRADURE, a Biopump producing interferon-alpha in preclinical stage for the treatment of hepatitis-C; and HEMODURE, a Biopump to produce clotting Factor VIII for the treatment of hemophilia. Medgenics, Inc. was founded in 2000 and is based in San Francisco, California.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/12/2015 8:25 AM Buy
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy